INTRODUCTION

Asthma is a chronic inflammation characterized by airway hyperresponsiveness, airway narrowing, mucus overproduction, and airway remodeling. Airway inflammation via secretion of pro-inflammatory cytokines is essential for asthma development. These cytokines orchestrate allergic immune responses including T cell differentiation, IgE production, and leukocyte activation.1,2 Traditionally, allergic inflammation has been considered the result of environmental allergens such as dust mites, pollens, and animal dander. However, recent studies propose that bacteria-derived toxins or components can also be involved in allergic responses. Little is known about the mechanism by which environmental microbiota might contribute to allergic reactions.

A recent metagenomic data analysis revealed a microbiome in the respiratory tract, which was once believed to be sterile, mainly because of difficulties in culturing the bacteria.3 Yet the airway is external to the body, and this space is thus a primary site for exposure to environmental factors such as bacteria and viruses. Differing compositions of lung microbiota between asthmatic and healthy people imply that bacteria might contribute to the development of disease.4,5 It is suggested that the local microbiota can directly affect airway-resident cells. However, the microbiota residing at other sites such as the gut might also affect lung immune responses. Further studies might elucidate interactions between the microbiota and the immune system that contribute to asthma.

An effective immune response requires appropriate cytokines and other inflammatory mediators produced by infected or resident cells. Microbiota- and host-derived molecules such as extracellular vesicles (EVs) might also regulate inflammation. EVs are lipid bilayers containing transmembrane proteins, cytosolic proteins, lipids, and nucleic acids with a diverse range of sizes (100-1,000 nm in diameter). As these molecules have surface ligands that interact with receptors on target cells, they can attach and modify the physiological state of recipient cells.6,7 Recent studies have demonstrated that EVs are involved in development of cancer, atherosclerosis, diabetes, meningitis, and...
Microbiota and immune responses of asthma

Asthma is a worldwide disease commonly characterized by eosinophilic inflammation. Given the large number of eosinophils in the airways, asthma is considered a hallmark of T helper type 2 (Th2) disorders of the lungs. The Th2 response is generally driven by the cytokines IL-4, IL-5, IL-9, and IL-13, which promote increased numbers of eosinophils in the airway and lead to high IgE levels in the blood. In mice, depletion of Th2-associated cytokines or induction of the Th1 response has reduced asthma features. However, there is an increasing interest in understanding the non-Th2 response, which likely represents a large proportion of asthma cases. The non-Th2 response involves adult-onset and severe asthma, which have a mixed Th1 and Th17 response with neutrophilic inflammation. In mice models of asthma, IL-17 has been strongly linked to neutrophilic inflammation, and has led to corticosteroid resistance. Severe asthma driven by IL-17 pathologically correlated with steroid-resistant asthma. Neutrophilic asthma has been linked to upregulation in TNF-α pathways, but it remains uncertain whether TNF blockade could improve steroid responsiveness. Although 2 forms of asthma have been defined, Th2 and non-Th2 responses co-occur in many cases, rather than being mutually exclusive.

Similar to many chronic inflammatory diseases, the pathogenesis of asthma mainly depends on genetic susceptibility and environmental factors. Environmental changes are a major factor in the development of allergic diseases. The recent microbiota hypothesis has suggested that perturbations in the gut microbiota disrupt the mucosal tolerance. A balance between the microbiota and host that maintains functional homeostasis is accurately regulated; however, it is constantly challenged by several factors. Once pathogenic bacteria colonize a niche, they cause a state of dysbiosis in the microbial community, which is now recognized to induce allergic diseases such as asthma (Table).

Airway microbiota and asthma

The presence of certain bacteria in the airway can regulate allergic inflammation. Haemophilus influenzae might be related to neutrophilic asthma, in which inflammation is mainly induced by neutrophils. Another well-known pathogenic bacterium, Staphylococcus aureus, is thought to be involved in severe asthma, since asthmatic patients have presented high levels of specific antibodies against S. aureus enterotoxins. Other bacteria such as Moraxella catarrhalis and Streptococcus pneumoniae have also been associated with childhood asthma. However, not all bacteria in the airway aggravate the severity of asthma; for example, Lactobacillus rhamnosus has protective effects against respiratory infection. Specific bacteria seem to modulate allergic inflammation; however, whether a single bacterial species can induce allergic disease is still unclear.

Recent studies have revealed that the composition of the microbiota residing in the lung can be more important in allergic diseases than the simple presence of individual species. Analyses of 16S rRNA have found that the airway hosts a complex community of microbes; moreover, bacterial populations of asthmatic patients are unlike those of healthy control subjects. The bacterial compositions of bronchial samples have also exhibited differences between 2 groups. These reports indicate that the phylum Proteobacteria was relatively prevalent in asthmatics, while phylum Bacteroidetes predominated in healthy controls. It has become clear that microbial community dysbiosis correlates with asthma. Diverse bacterial communities reside in the airway, and altered composition of these microbiota might contribute to allergic inflammation in asthma.

Clinical studies of corticosteroid inhalation suggest that the airway microbiota affects corticosteroid responsiveness among asthmatic patients. Bacterial community profiles of corticosteroid-sensitive or -resistant asthmatics were not well discerned, but Haemophilus parainfluenzae was observed in some of the corticosteroid-resistant asthmatics. Another study of antibiotic treatment observed azithromycin-induced modification of the airway microbiota of adult asthmatic patients. The abundance of members of the Haemophilus and Pseudomonas genera de-
clined within the community, but the abundance of *Anaerococcus* species increased. These findings suggest that the airway microbiota drives asthma development, and explain corticosteroid responsiveness. We expect that current efforts to understand the airway microbiome membership in detail will help reveal a mechanistic link between the microbiota and asthma.

**Gut microbiota and asthma**

The airway microbiota can shape lung-specific immune responses resulting in either homeostatic or detrimental inflammation. Recently, the gastrointestinal (GI) tract microbiome has also become a plausible influencer of immune development against allergy or asthma. This interest in GI microbes stemmed from an observed inverse relationship between rate of childhood asthma and exposure to bacteria in infancy. Moreover, infants who develop asthma have presented relatively few *lactobacillus*, and *bifidobacteria*, and relatively many *enterococcus*. Further studies indicate that the gut microbiota influences the maturation of immune function in early life through the oral ingestion of environmental bacteria.

Studies in mice also provide strong evidence of the role of gut microbiota in the regulation of immune function. Germ-free (GF) mice presented strong allergic inflammation compared to specific pathogen-free (SPF) mice through OVA sensitization and challenge. Specific bacteria like *Lactobacillus reuteri* exhibited the protective effects of inducing regulatory T (Treg) cell expansion and reducing inflammation, in response to OVA challenge in sensitized BALB/c mice. Treatment with *Clostridium* strains produced similar effects on Treg cells in the colonic mucosa, and reduced IgE levels after OVA sensitization. Interestingly, segmented filamentous bacteria induced Th17 cell expansion, which mediates mucosal defense in the lamina propria. However, a recent study found that direct ingestion of certain bacteria was insufficient to induce significant changes in immune function.

Experimental feeding of different dietary components indicated that dietary changes could affect allergic inflammation by modifying the microbiota composition. High fiber diet altered the ratio of *Firmicutes* spp. to *Bacteroidetes* spp., and increased the levels of circulating short-chain fatty acids. These subsequent alterations protected against allergic lung inflammation via activation of Treg cells. The mechanisms of Treg-mediated suppression are not fully understood, but microbes do promote Treg cell activation by maintaining resident dendritic cells (DCs) in an immature state, which is essential for mucosal tolerance.

The propensity of an innocuous antigen to induce local and systemic immune unresponsiveness is termed as oral tolerance. In the large intestine, commensal bacteria are also regulated by an analogous, but more locally processed, tolerance. It is assumed that oral tolerance and airway tolerance are tightly linked, and that the GI tract might act as a sensor for the development of tolerance to antigens. However, it remains to be determined how changes in the gut microbiota affect lung immunity.

**EVs as mediators of allergic disease**

Immune system recognition of pathogens is essential to activating immune cells. Bacterial components that trigger immune response are often referred to as pathogen-associated molecular patterns (PAMPs); these components include carbohydrates, lipids, proteins, and genetic material. PAMPs can bind to pattern recognition receptors (PRRs) on immune and non-immune cells, thereby initiating signaling cascades. Given their role in the immune system, pathogens have evolved to increase their virulence by modulating their signals to PRRs. Recent studies report that both PAMPs and EVs released from infected cells and pathogens are likely to be involved in immune responses.

EVs are released by diverse cell types that have been implicated in allergic responses such as bronchial epithelial cells, mast cells, dendritic cells, and T cells in the lung. Bronchial epithelial cells are the primary producers of EVs in the lungs of patients with asthma. Interestingly, it was found that IL-13-stimulated bronchial epithelial cells released EVs that promoted proliferation of macrophages, but reduction in EV secretion seemed to ameliorate asthmatic features. During allergic inflammation, mast cell-derived EVs were highly activated, and contributed to induction of DC maturation. DCs also produce EVs that present allergens and activate allergen-specific Th2 cells. Many studies suggest that EVs can transfer MHC/antigen complexes, enabling the DCs to efficiently activate T cells. These observations indicate the potential contributions of diversely sourced EVs to the pathogenesis of asthma. In contrast, some studies have reported that EVs can inhibit Th2 response-associated cytokine production, IgE response, and even prevent the development of asthma. While immune cells mediate immune responses, non-immune cells such as bacteria also have important roles in activating immune responses. EVs produced by pathogens such as *Staphylococcus aureus* have been implicated in atopic dermatitis-like skin inflammation; these EVs might also induce neutrophilic pulmonary inflammation. EVs derived from *E. coli* induce several infectious diseases, and can aggravate emphysema through IL-17A-mediated neutrophilic inflammation. *Pseudomonas aeruginosa* often contributes to lung diseases such as cystic fibrosis, and its EVs increase pulmonary inflammation through Toll-like receptor (TLR)2 and TLR4 pathways. Moreover, indoor dust, which contains many components of bacteria, has been associated with both Th1 and Th17 responses, which induce neutrophilic pulmonary inflammation. As bacteria-derived EVs can affect distal host cell sites, these vesicles might play significant roles throughout the body. Here, we propose a model that uses EVs to link the environmental microbiota with airway immunity (Figure).
CONCLUSIONS

The presence of lung and gut dysbiosis in asthma suggests that microbiota composition might shape the immune system and lead to the development of asthma. Microbial communities have immunomodulatory roles in both the disease progression and the clinical outcome of asthma, but our understanding of mechanisms linking gut- to lung-immunity is still unclear. EVs might provide new insights into immune responses, as they can move to distant sites and stimulate other cells such as immune and epithelial cells. EVs produced by commensal bacteria can benefit the host by promoting mucosal tolerance and protecting against the onset of diseases. However, questions remain as to which components of EVs activate recipient cells and how EVs regulate intracellular signaling pathways. Further studies will provide a mechanistic understanding of interactions between the microbiota and the host immune response through EVs, which in turn will aid in providing new insights into the management of asthma.

ACKNOWLEDGMENTS

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, ROK (HI14C2628).

ORCID

Hae-Sim Park http://orcid.org/0000-0003-2614-0303

REFERENCES

1. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789-815.
2. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999;17:255-81.
3. Suau A, Bonnet R, Sutren M, Godon JJ, Gibson GR, Collins MD, et
Microbiota, Extracellular Vesicles, and Asthma

al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999;65:4799-807. 11. Hilly M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010;5:e8578. 12. Charlson ES, Bittinger K, Chen J, Diamond JM, Li H, Collman RG, et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS One 2012;7:e42786. 13. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83. 14. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89. 15. Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cuvelier CA, Pauwels RA, et al. Attenuation of allergic airway inflammation and airflow limitation in adults with asthma. Chest 2007;132:1871-5. 16. Gavett SH, O’Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-36. 17. Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Ann Allergy Asthma Immunol 2010;1129-33. 18. Manni ML, Trudeau JB, Scheller EV, Mandalapu S, Elloso MM, Kolls JK, et al. The complex relationship between inflammation and lung function in severe asthma. Mucosal Immunol 2014;7:1186-98. 19. Duka S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Diener K, et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental asthma. Nat Immunol 2010;11:928-35. 20. Kim BJ, Lee SY, Kim HB, Lee E, Hong SJ. Environmental changes, microbiota, and allergic diseases. Allergy Asthma Immunol Res 2016;8:92-100. 21. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-9. 22. Novero MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 2005;35:1511-20. 23. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 2006;7:956-70. 24. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med 2014;20:642-7. 25. Essafi AT, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012;67:588-99. 26. Bachert C, Gevaert P, Howarth P, Holtappels G, van Cauwenberge P, Johansson SG. IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma. J Allergy Clin Immunol 2003;111:1131-2. 27. Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol 2012;130:376-81. 28. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer JB, Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007;357:1487-95. 29. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014;30:255-89. 30. Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cuvelier CA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007;132:1871-5. 31. Gavett SH, O’Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-36. 32. Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Ann Allergy Asthma Immunol 2010;1129-33. 33. Manni ML, Trudeau JB, Scheller EV, Mandalapu S, Elloso MM, Kolls JK, et al. The complex relationship between inflammation and lung function in severe asthma. Mucosal Immunol 2014;7:1186-98. 34. Kim BJ, Lee SY, Kim HB, Lee E, Hong SJ. Environmental changes, microbiota, and allergic diseases. Allergy Asthma Immunol Res 2016;8:92-100. 35. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-9. 36. Novero MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 2005;35:1511-20. 37. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep 2006;7:956-70. 38. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, et al. Lung microbiota promotes tolerance to allergens in
ma and allergy in rural and suburban populations across Europe. Clin Exp Allergy 2007;37:661-70.

39. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microbiota during the first year of life. J Allergy Clin Immunol 2001;108:516-20.

40. Kalliomaki M, Kirjavainen P, Errola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microbiota in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-34.

41. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007;56:661-7.

42. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012;336:489-93.

43. Rautava S, Luoto R, Salminen S, Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. Nat Rev Gastroenterol Hepatol 2012;9:565-76.

44. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012;13:440-7.

45. Herbst T, Sichelstiel A, Schar C, Yadava K, Burki K, Cahenzli J, et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med 2011;184:198-205.

46. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 2011;184:186-93.

47. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337-41.

48. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-98.

49. Trumpet AE, Goldwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bruc C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014;20:159-66.

50. Thorburn AN, McKenzie DJ, Shen S, Stanley D, Macia L, Mason LJ, et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat Commun 2015;6:7320.

51. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007;7:875-88.

52. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-5.

53. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003;3:331-41.

54. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.

55. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 2007;110:3234-44.

56. Pyun BY. Extracellular Vesicle: An Unknown Environmental Factor for Causing Airway Disease. Allergy Asthma Immunol Res. 2016;8:179-80.

57. Kulshreshtha A, Ahmad T, Agrawal A, Ghosh B. Proinflammatory role of epithelial cell-derived exosomes in allergic airway inflammation. J Allergy Clin Immunol 2013;131:194-203, 203 e1-14.

58. Skokos D, Botros HG, Demuee C, Morin J, Peronnet R, Birkenmeier G, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 2003;170:3037-45.

59. Admure C, Telemero E, Almqvist N, Lotvall J, Lahnema R, Scheinys A, et al. Exosomes - nanovesicles with possible roles in allergic inflammation. Allergy 2008;63:404-8.

60. Hsu DH, Paz P, Villafior G, Rivas A, Mehta-Damani A, Angevin E, et al. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother 2003;26:440-50.

61. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004;172:2126-36.

62. Prado N, Marazuela EG, Segura E, Fernandez-Garcia H, Villalba M, Thery C, et al. Exosomes from bronchoalveolar fluid of tolerant mice prevent allergic reaction. J Immunol 2008;181:1519-25.

63. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation. Allergy 2011;66:351-9.

64. Hong SW, Choi EB, Min TK, Kim JH, Kim MH, Jeon SG, et al. An important role of alpha-hemolysin in extracellular vesicles on the development of atopic dermatitis induced by Staphylococcus aureus. PLoS One 2014;9:e100499.

65. Kim MR, Hong SW, Choi EB, Lee WH, Kim YS, Jeon SG, et al. Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 2012;67:1271-81.

66. Kim YS, Lee WH, Choi EJ, Choi JP, Heo YJ, Gho YS, et al. Extracellular vesicles derived from Gram-negative bacteria, such as Escherichia coli, induce epithysema mainly via IL-17A-mediated neutrophilic inflammation. J Immunol 2015;194:3361-8.

67. Park KS, Lee J, Jang SC, Kim SR, Jang MH, Lotvall J, et al. Pulmonary inflammation induced by bacteria-free outer membrane vesicles from Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 2013;49:637-45.

68. Kim YS, Choi EJ, Lee WH, Choi SJ, Roh TY, Park J, et al. Extracellular vesicles, especially derived from Gram-negative bacteria, in indoor dust induce neutrophilic pulmonary inflammation associated with both Th1 and Th17 cell responses. Clin Exp Allergy 2013;43:443-54.

69. Kim YS, Choi JP, Kim MH, Park HK, Yang S, Kim YS, et al. IgG Sensitization to Extracellular Vesicles in Indoor Dust Is Closely Associated With the Prevalence of Non-Eosinophilic Asthma, COPD, and Lung Cancer. Allergy Asthma Immunol Res. 2016;8:198-205.

70. Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 2010;74:81-94.